Member Info for SGD27

We don't need or want to be part of ACCORD or RECOVERY or SOLIDARITY or anything else.

We are independent.

We pay our own bills.

We will be under no pressure to share our profits, if successful.

I think these people might be a bit miffed that their name has been usurped :-(

https://www.accord.scot/

@ChrisToffler : I agree, it's good forward planning. It's been noted before that the EU Register document states up to 400 subjects. So the pilot phase was 100, in hospitals, and keep options open where to take it next.

I think the 'non-hospitalised patients' clause has been here for ages :

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB

Hi Bosi, welcome, and thanks for that. Yes, it does look new, and again supports the idea that our biggest challenge is getting the treatment started soon enough.

I know new posters can't do links, so here it is :

https://www.hra.nhs.uk/covid-19-research/approved-covid-19-research/281317/

Hi ShareSting, I'm not sure that we should seek financial support from the government. The point being that if we're footing 100% of the bills then we're entitled to 100% of the rewards!

https://www.bbc.co.uk/news/live/world-52450742

Around 17:09

https://www.vo%78markets.co.uk/articles/vadim-alexandre-on-novacyt-synairgen-hemogenyx-and-polarean-plus-glen-goodman-3d49d3b

Synairgen discussed briefly from ~12:00 in.

This is a proactive interview with Pharmaxis today. LOXL2 is not the main topic of conversation, but it does get mentioned (from around 4:40) with some hints that there might be news before too long.

(Reminder for anyone unfamiliar - SNG has a ~17% interest in this LOXL2 programme.)

https://www.proactiveinvestors.co.uk/companies/news/918279/pharmaxis-to-progress-myelofibrosis-drug-to-phase-ii-following-positive-results-918279.html

I found this bit of RM's email very interesting (and new?) :

"However, there is the possibility that ACE2 was shed from the cell surface after up-regulation in response to IFN treatment. While this was not investigated, if it did occur, it would provide additional protection as the sACE2 would ‘mop up’ the virus before it can infect the cells."

So if I understand correctly, he's saying yes, interferon might be creating more ACE2 protein, but if it's shed from the cell then rather than assisting the virus it will act as a decoy!

At the end of the day it seems to me that this is very much an experimental rather than theoretical science, and VERY complicated. So I can understand that some will see our amateur technical discussions as pointless. But at least it helps me to understand what it is that I don't understand, which improves my investment risk assessment. I'm still in BTW.

@Trek : Interesting, your comments are a bit beyond me, but I will attempt to understand them later!

References:

https://www.sciencemag.org/news/2020/04/these-drugs-don-t-target-coronavirus-they-target-us

and

https://www.biorxiv.org/content/10.1101/2020.01.31.929042v1.full.pdf

Respectively :
? = alpha
? = beta
? = gamma
??? = (probably?) gamma

I think it's just a character-set problem, but you can work it all out from the paper I just posted.

For reference, this is he research paper being referred to :

https://www.cell.com/pb-assets/products/coronavirus/CELL_CELL-D-20-00767.pdf

Miggy (& ShareSting), many thanks for sharing that, it does sound reassuring.

The mRNA vs protein expression thing had completely passed me by, so now I'll have to have another go at rereading that impenetrable research paper!

I don't think it was wrong for the "troubled few" of us to raise the ACE2 issue, but thanks to your effort we're perhaps a little less troubled now :-)

ATB & Thanks again.

I meant RM's body language, not yours :-)

But it's head & shoulders only, so might not be enough?

@Groover : Ask your wife how she reads the body language - they're usually much better at that than we are!

It was BRR not proactive :

https://www.brrmedia.co.uk/broadcasts/5e95b44e31da814c9fc6929e/finncap-short-interview-with-richard-marsden-ceo-synairgen

"At a market cap of £75m ..."

Wrong - fails to take into account the new shares (as does LSE at the moment).

Interesting that the Leicester site says they are recruiting "patients who have confirmed COVID-19 and pneumonia" for the SNG001 trial.